NTCP binder peptide WD1
CAS No. ——
NTCP binder peptide WD1( —— )
Catalog No. M17088 CAS No. ——
NTCP binder peptide WD1 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNTCP binder peptide WD1
-
NoteResearch use only, not for human use.
-
Brief DescriptionNTCP binder peptide WD1 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV.
-
DescriptionNTCP binder peptide WD1 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=15 nM), reduces HBs antigen levels in culture supernatants; also inhibits cellular entry by the related hepatitis D virus (HDV), and is active against diverse strains of HBV (including clinically relevant nucleos(t)ide analog-resistant and vaccine escaping strains); exhibitsno inhibition of NTCP-mediated bile acid uptake in contrast to other NTCP-binding HBV entry inhibitors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight1917.216
-
Molecular FormulaC95H125N19O22S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameCyclo-s-Ac-d-Tyr-Phe-Ile-Ile-ValMe-Gly(Me)-Thr-Trp-Thr-Trp-Thr-Trp-Ser-Cys-Thr-NH2
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Passioura T, et al. Cell Chem Biol. 2018 Jul 19;25(7):906-915.e5.
molnova catalog
related products
-
JNJ-632
JNJ-632 (JNJ632) is a novel potent HVV capsid assembly modulator and HBV replication inhibitor.
-
AT-130
AT-130 is a potent inhibitor of HBV capsid assembly, inhibits wild-type HBV replication with IC50 of 2.4 uM.
-
Burfiralimab
Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.
Cart
sales@molnova.com